TFF Pharmaceuticals, Inc.
TFFP · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | -0.03 | 0.07 |
| FCF Yield | -22.52% | -49.84% | -20.54% | -25.65% |
| EV / EBITDA | -1.74 | -0.56 | -2.18 | -2.15 |
| Quality | ||||
| ROIC | -110.49% | -65.76% | -111.01% | -56.15% |
| Gross Margin | 100.00% | 78.38% | 31.04% | 82.19% |
| Cash Conversion Ratio | 0.56 | 0.73 | 0.55 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,211,989.14% | 1,166,420.45% | 1,082,972.81% | 1,037,981.71% |
| Free Cash Flow Growth | 39.16% | -3.47% | 26.19% | -41.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 1.09 | 0.56 | 1.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -34.65 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -814.40 | -940.69 | -606.95 |